What do you monitor?
Curated feeds for your role. Pick your area and get exactly the sources you need.
Compliance & Legal
Legal Research
Court opinions, regulatory guidance, and enforcement actions. AI-summarized.
Financial Compliance
SEC, OCC, FDIC, Fed, FINRA, CFPB, FASB, and state banking regulators. One feed.
Insurance Compliance
State commissioner bulletins, NAIC model laws, and DOI enforcement actions.
Environmental Compliance
EPA enforcement, state environmental agencies, PFAS regulatory updates.
Data Privacy
State AG privacy enforcement, FTC actions, CPPA rulemaking, and HIPAA enforcement.
Tax Compliance
IRS guidance changes and state tax department bulletins.
AML Compliance
FinCEN, OCC, FDIC, Fed, FATF, and banking regulator enforcement.
Labor & Employment
NLRB decisions, EEOC guidance, DOL wage updates, and 50-state labor law changes.
Immigration Law
USCIS policy changes, visa bulletin updates, CBP processing changes.
Industry
Pharma & Life Sciences
FDA warning letters, drug approvals, ICH guidelines, EMA updates, and DEA scheduling.
Energy & Utilities
FERC orders, state PUC decisions, and energy regulatory changes.
Cybersecurity
CISA KEV catalog, ICS-CERT, NSA advisories, NIST CSF, and FedRAMP updates.
Healthcare Compliance
CMS transmittals, OIG work plan, HIPAA enforcement, and Medicaid updates.
Trade & Procurement
Recent changes
Medicare.gov Enhanced Login Options
The Centers for Medicare & Medicaid Services (CMS) has introduced new login options for Medicare.gov, including ID.me, CLEAR, and Login.gov, to enhance user security and protect beneficiary information from fraud and identity theft. These services are free and offer various verification and support methods.
FDA Approves Filgrastim-LAHA Biosimilar
The FDA has approved FILKRI (filgrastim-LAHA), a biosimilar product, for ACCORD BIOPHARMA INC. The approval was granted on January 15, 2026, under Biologic License Application (BLA) 761027. This marks the addition of a new biosimilar option to the market.
FDA Approves Ranibizumab-leyk Biosimilar (NUFYMCO)
The FDA has approved the Biologic License Application (BLA) 761473 for NUFYMCO (ranibizumab-leyk) from FORMYCON AG. This approval marks the addition of a new biosimilar product to the market.
FDA Approves ARMLUPEG (Pegfilgrastim-unne) Biosimilar
The FDA has approved ARMLUPEG (pegfilgrastim-unne), a biosimilar drug manufactured by LUPIN LTD. This approval marks the addition of a new biosimilar product to the market, following the FDA's review process.
FDA Approval of JUBEREQ and OSVYRTI (denosumab-desu)
The FDA has approved Biologic License Application (BLA) 761424 for JUBEREQ and OSVYRTI, both containing the active ingredient denosumab-desu, submitted by ACCORD BIOPHARMA INC. This approval marks the addition of new prescription injectable medications to the market.
FDA Issues Emergency Use Authorization for Ivomec to Prevent Screwworm in Cattle
The FDA has issued an Emergency Use Authorization (EUA) for Ivomec (ivermectin) injectable solution to prevent New World screwworm infestations in cattle. This authorization allows for over-the-counter use under specific conditions and is effective until the declared emergency is terminated.
FDA Issues Emergency Use Authorization for F10 Antiseptic Wound Spray for New World Screwworm
The FDA has issued an Emergency Use Authorization (EUA) for F10 Antiseptic Wound Spray with Insecticide for the prevention and treatment of New World screwworm in multiple animal species, excluding domestic dogs and cats. This authorization allows for broader use than previously approved products, with specific food safety guidelines for treated animals.
FDA Authorizes Drugs for New World Screwworm in Dogs and Cats
The FDA has issued two Emergency Use Authorizations (EUAs) for NexGard and NexGard COMBO for the treatment of New World screwworm infestations in dogs and cats, respectively. These EUAs are effective until the HHS Secretary terminates the public health emergency declaration for this pest.
FDA Guidance on Defining Drug Use Durations for Medically Important Antimicrobials
The FDA has finalized guidance (GFI #273) recommending how animal drug sponsors can voluntarily establish defined durations of use for medically important antimicrobial drugs administered in feed to food-producing animals. Over 100 drugs are affected, and sponsors are expected to submit revised labeling within approximately three years.
FDA Approves First Generic Florfenicol and Flunixin Injection
The FDA has approved nixiFLOR, the first generic version of florfenicol and flunixin meglumine injection for treating bovine respiratory disease. This approval marks a new generic option for beef and non-lactating dairy cattle, with a withdrawal period of 38 days.
Browse by category
US Federal
998 sources
US State
116 sources
US Courts
122 sources
UK
77 sources
EU
71 sources
Canada
28 sources
Courts & Legal
312 sources
Government & Legislation
258 sources
Banking & Finance
228 sources
Healthcare
131 sources
Trade & Sanctions
124 sources
Labor & Employment
110 sources
Energy
104 sources
Pharma & Drug Safety
94 sources
Environment
83 sources
Securities & Markets
75 sources
Data Privacy & Cybersecurity
62 sources
Tax
62 sources
Agriculture & Food Safety
61 sources
Transportation
56 sources
Insurance
55 sources
Defense & National Security
48 sources
Telecom & Technology
42 sources
Consumer Protection
40 sources
Education
20 sources
Housing
15 sources
Immigration
9 sources
Legal & Courts
1 sources
Browse by agency
ESMA
3 sources
ICE
3 sources
AHRQ
3 sources
State Pharmacy
3 sources
State Consumer Protection
3 sources
FMCSA
3 sources
NY Courts
3 sources
BaFin
3 sources
OR Courts
3 sources
CRB
3 sources
PBGC
3 sources
KS Courts
3 sources
SFO
3 sources
DOI
3 sources
AL Courts
3 sources
State BOA
3 sources
FATF
3 sources
TN Courts
3 sources
AMF France
3 sources
NCSC
3 sources
Get alerts when regulations change
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.